கணக்கீட்டு மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SwabSeq platform offers a potential solution for massive COVID-19 testing In an article appearing in Nature Biomedical Engineering, a team of scientists from the UCLA David Geffen School of Medicine and UCLA School of Engineering report real-world results on SwabSeq, a high-throughput testing platform that uses sequencing to test thousands of samples at a time to detect COVID-19. They were able to perform more than 80,000 tests in less than two months, with the test showing extremely high sensitivity and specificity. SwabSeq uses sample-specific molecular barcodes to simultaneously analyze thousands of samples for the presence or absence of SARS-CoV-2, the virus that causes COVID-19. SwabSeq was granted FDA Emergency Use Authorization in October and is currently deployed at UCLA in a high-complexity CLIA laboratory, which has performed over 150,000 tests since December 2020. SwabSeq is a flexible protocol and can rapidly scale up testing for novel pathogens, including COVID-19 and

United statesLos angelesValerie arboledaEmily hendersonUniversity of californiaDepartment of computational medicineDavid geffen school of medicineDepartment of human geneticsSchool of engineeringLaboratory medicineDepartment of pathologyLos angeles health sciencesSamueli school of engineeringNature biomedical engineeringGeffen schoolUse authorization